found that in ERα-positive breast cancers that were responsive to Sox2, DDX17 was a transcriptional coactivator of Sox2 and promoted the transcription of Sox2 target genes to promote the malignant development of breast cancer (16). The gene discussed is ESR1; the disease is breast carcinoma.